Computer-aided breast cancer drug screening method and system

Abstract

The invention discloses a computer-aided breast cancer drug screening method and system, finds that miR-223-3p plays a role in regulating and controlling proliferation and apoptosis of breast cancer cells by regulating and controlling KIF4A for the first time, and provides a computer-aided drug screening method, system and equipment based on miR-223-3p and KIF4A and a computer readable storage medium based on miR-223-3p and KIF4A.

Description

Technical Field

[0001] The present invention belongs to the technical field of computer-aided drug screening, and in particular, relates to a computer-aided breast cancer drug screening method and system. Background Art

[0002] There are more than 2 million new cases of breast cancer each year, accounting for about one-eighth of all cancer diagnoses, and it has become the most common cancer in the world. According to the progression of the tumor, breast cancer can be divided into ductal carcinoma in situ, early invasive stage, locally advanced stage and tumor metastasis stage. Effective treatment methods are selected according to the cancer stage. Currently common treatment methods include breast lumpectomy, mastectomy, radiotherapy, chemotherapy, endocrine therapy and immunotherapy. Due to the heterogeneity of breast cancer, studying the molecular mechanisms of tumor occurrence has become relatively complicated. Treatment resistance has also led to higher requirements for different treatment options. Therefore, studying the molecular mechanisms and signaling pathways of tumor development will help discover diagnostic markers and apply new treatment strategies. Summary of the invention

[0003] In order to address the deficiencies of the prior art, the present invention discovered the interaction between miR-223-3p and KIF4A, and based on this, developed a computer-assisted drug screening method and system, and used the method to screen drugs for treating and / or preventing breast cancer.

[0004] The first aspect of the present invention provides a computer-assisted drug screening method based on miR-223-3p and KIF4A, the computer-assisted drug screening method based on miR-223-3p and KIF4A comprising:

[0005] Obtain miR-223-3p and KIF4A gene data;

[0006] Selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug;

[0007] A computer-assisted drug screening method is used to obtain candidate drugs targeting the binding site.

[0008] The second aspect of the present invention provides a computer-assisted drug screening system based on miR-223-3p and KIF4A, characterized in that the computer-assisted drug screening system comprises:

[0009] Data acquisition unit: obtain miR-223-3p and KIF4A data;

[0010] Site determination unit: selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug;

[0011] Drug screening unit: computer-assisted drug screening method is used to obtain candidate drugs targeting the binding site.

[0012] The third aspect of the present invention provides a computer-assisted drug screening device based on miR-223-3p and KIF4A, characterized in that the device comprises:

[0013] A memory and a processor, wherein the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, the computer-assisted drug screening method based on miR-223-3p and KIF4A described in the first aspect of the present invention is performed.

[0014] The fourth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, and when the computer program is executed by a processor, the computer-assisted drug screening method based on miR-223-3p and KIF4A described in the first aspect of the present invention is implemented.

[0015] The fifth aspect of the present invention provides the use of candidate drugs screened by the computer-assisted drug screening method based on miR-223-3p and KIF4A described in the first aspect of the present invention in the treatment of breast cancer.

[0016] A sixth aspect of the present invention provides a method for regulating KIF4A, the method comprising administering a regulator of miR-223-3p.

[0017] In one embodiment, when the modulator promotes miR-223-3p, KIF4A is significantly downregulated; when the modulator inhibits miR-223-3p, KIF4A is significantly upregulated.

[0018] In one embodiment, KIF4A is a downstream target of miR-223-3p, which inhibits the proliferation and invasion of breast cancer cells by regulating the expression of KIF4A.

[0019] The advantages and beneficial effects of the present invention are as follows:

[0020] The present invention discovers for the first time that miR-223-3p inhibits the proliferation and invasion of breast cancer cells by directly targeting and downregulating the expression of KIF4A. Based on this discovery, the present invention develops a computer-assisted drug screening method and system, and uses the method to screen drugs for the treatment and / or prevention of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0022] Figure 1 It is a schematic flow chart of a computer-assisted drug screening method based on miR-223-3p and KIF4A provided in an embodiment of the present invention;

[0023] Figure 2 This is a schematic diagram of TargetScan predicting miR-223-3p online targeting KIF4A provided by an embodiment of the present invention;

[0024] Figure 3 is a schematic diagram of KIF4A mutation provided by an embodiment of the present invention;

[0025] Figure 4 Schematic diagram of a computer-assisted drug screening system based on miR-223-3p and KIF4A provided in an embodiment of the present invention;

[0026] Figure 5 It is a schematic diagram of a computer-assisted drug screening device based on miR-223-3p and KIF4A provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0027] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0028] In some of the processes described in the specification and claims of the present invention and the above-mentioned drawings, multiple operations appearing in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this document or may be executed in parallel. The serial numbers of the operations, such as S101, S102, etc., are only used to distinguish different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel.

[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0030] Figure 1 1 is a flow chart of a computer-assisted drug screening method based on miR-223-3p and KIF4A provided by an embodiment of the present invention. Specifically, the method comprises the following steps:

[0031] S101: Obtaining miR-223-3p and KIF4A gene data;

[0032] In one embodiment, the gene data of KIF4A is obtained, and TargetScan is used to predict the microRNAs and binding sites that regulate KIF4A expression. The microRNAs predicted to regulate KIF4A expression are ranked by percentage, and the ranking is based on the evolutionarily conservative target probability (Pct score). miR-223-3p has the highest score, and it is speculated that miR-223-3p may regulate KIF4A expression ( Figure 2 );

[0033] S102: selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug;

[0034] In one embodiment, the binding sites of miR-223-3p and KIF4A predicted by TargetScan (https: / / www.targetscan.org / ) were selected and compared with the 3′-UTR of KIF4A, and KIF4AMUT was designed for the binding sites so that KIF4A no longer binds to miR-223-3p after mutation ( Figure 3). The 3'-UTR of KIF4A was searched, and PCR for amplifying the 3'-UTR sequence of KIF 4A was designed using Primer premier 5.0. The reporter gene vector pmirGLO- was obtained by connecting the cleavage sites of Xho I and SalI enzymes to the pmirGLO vectors KIF4A-WT and pmirGLO-KIF4A-Mut. The reporter gene vector and mRNA-223-3p were co-introduced into breast cancer cells T47D cells. After 48 hours of infection, detection was performed using a dual luciferase reporter gene assay kit (RG 027, Beyotitime, Shanghai, China) and a Promega Glo Max 20 / 20 luminescence detector (YPH Bio, Beijing, China). The ratio of Firefly Luciferase to Renilla Luciferase was calculated to correct for differences in transfection efficiency and cell growth status. The changes in luciferase activity between WT and Mut vectors under mimics and NC treatment were compared to evaluate the regulatory effect of miR-223-3p on KIF4A 3'UTR. After treatment with miR-223-3p mimics, the luciferase activity in cancer cells transfected with KIF4A WT was significantly decreased, while the luciferase activity in cells transfected with miR-223-3p inhibitor and KIF4A WT was significantly increased, and these changes were not observed after treatment with KIF4A MUT, indicating the direct binding of miR-223-3p to the 3'-UTR of KIF4A.

[0035] To investigate the interaction between miR-223-3p and KIF4A in breast cancer cells, we overexpressed KIF4A and miR-223-3p mimics in breast cancer cells. Overexpression vectors were constructed using pc-DNA3.1 plasmid, and BamHI and EcoRI were selected as restriction sites for primer design. All primers were synthesized by Guangzhou Ruibo Biotechnology Co., Ltd. (Shanghai, China). MDA-MB-231 and T47D cells and pcDNA3.1-KIFD4A were transfected with Lipofectamine 2000 (Fisher Scientific, USA), respectively. miR-223-3p mimics and microRNA mimic negative control (Med Chemical Expression, USA) were dissolved in nuclease-free water to obtain a 20 μM stock solution. T47D cells were transfected using PolyFast transfection reagent (MedChemExpress, USA). The cell culture medium was discarded, and RNA was extracted using RNA extraction reagent according to PrimeScript TM DNA was synthesized using the BeyoFast TMThe reaction system was prepared using the SYBR Green One-Step qRT-PCR Kit (D 7268S, Beyotime, Shanghai, China), and the reaction was performed using a real-time PCR amplification device (T100, Bio-Rad Labs, USA). ΔΔCT The data were quantitatively analyzed. The results of qRT-PCR showed that overexpression of KIF4A had no significant effect on the expression level of mRNA-223-3p.

[0036] The protein expression was detected by western blot, and the results showed that mRNA-223-3p mimics downregulated the expression of KIF4A in T47 D cells. The colony formation assay was used to detect the number of cell colonies, and the results showed that the number of cell colonies in the KIF4A overexpression group was the highest, and the number of cell colonies in the miR-223-3p overexpression group was the lowest, while the number of cell colonies in the miR-223-3p-mimics+KIF4A group was not significantly different from that in the blank control group. The Transwell assay was used to detect cell migration and invasion, and the results showed that compared with the control group, KIF4A overexpression significantly promoted the migration and invasion of T47 D cells, while miR-223-3p mimics significantly inhibited the migration and invasion of cells. KIF4A overexpression reversed the effect of miR-223-3p on cancer cells.

[0037] The ROS content was detected using a reactive oxygen species detection kit (S0033M, Shanghai Biyuntian Technology Co., Ltd.), and DCFH-DA was diluted 1:1000 in serum-free medium. After removing the cell culture medium, diluted DCFH-DA (1 mL) was added. Incubate in a 37°C incubator for 20 minutes. Wash the cells three times with serum-free cell culture medium. The results were observed using a confocal laser scanning microscope. The relative fluorescence intensity was determined using ImageJ software. The results showed that overexpression of KIF4A significantly weakened the fluorescence intensity, while miR-223-3p mimics significantly enhanced the fluorescence intensity, among which the fluorescence intensity of the miR-223-3p mimics+KIF4A group returned to normal. In addition, compared with the mimics-NC+Vector group, the MDA content in the mimics-NC+KIF4A group was significantly reduced, while the MDA content in the mimics-NC group was significantly upregulated. However, the effect of miR-223-3p-mimics on T47D cells was partially inhibited after co-transfection of miR-223-3p-mimics with KIF4A. In T47D cells, KIF4A overexpression promoted SOD expression, while miR-223-3p mimics inhibited SOD expression, and this inhibitory effect disappeared in the miR-223-3p-mimics-KIF4A group.

[0038] Cell apoptosis was detected using the Annexin V-Analyst / PI apoptosis detection kit (40302ES20, Yeasen, Shanghai, China). Flow cytometry results showed that KIF4A overexpression significantly reduced the mortality of T47D cells, while miR-223-3p mimics promoted the death of T47D cells. The cell mortality rate in the miR-223-3p-mimics+KIF4A group was not significantly different from that in the control group. A series of apoptosis-related proteins were detected by protein hybridization, among which Bax and cleaved Caspase-3 had the lowest expression in the KIF4A overexpression group and the highest expression in the miR-223-3p mimics group, while the expression of pro-apoptotic proteins in the miR-223-3p mimics+KIF4A treatment group was not significantly different from that in the control group. In addition, the expression of the anti-cell death protein Bax-2 was significantly upregulated in the KIF4A overexpression group but significantly downregulated in the mimic-NC group, and miR-223-3p mimics reversed the inhibitory effect of KIF4A on cell death.

[0039] The above results prove that miR-223-3p affects the proliferation, migration, invasion and apoptosis of breast cancer cells by regulating KIF4A. Based on this, the present invention develops a computer-assisted drug screening method based on miR-223-3p and KIF4A for the first time.

[0040] S103: Using a computer-assisted drug screening method to obtain a candidate drug targeting the binding site. In one embodiment, the computer-assisted drug screening method includes:

[0041] Obtain miR-223-3p and KIF4A binding sites;

[0042] Protein analogs / nucleic acid analogs / antibodies / RNA drugs are screened through the binding site to obtain candidate drugs.

[0043] In one embodiment, the protein analog / nucleic acid analog / antibody / RNA drug includes siRNA, shRNA, dsRNA, microRNA, antisense nucleic acid, antibody, polypeptide, protein analog, peptide analog.

[0044] In one embodiment, the computer-assisted drug screening method comprises:

[0045] Obtaining the binding site of miR-223-3p and KIF4A;

[0046] Based on the spatial structure of the binding site of miR-223-3p and KIF4A, screening small molecule compounds with similar structures in the molecular database;

[0047] The screened small molecule compounds are subjected to molecular docking with the KIF4A protein to calculate the affinity or binding energy of the small molecule compounds targeting the KIF4A protein to obtain the score of each small molecule compound, and the candidate drugs are obtained by ranking according to the score.

[0048] It should be noted that the present invention has no particular restrictions on the specific types of the small molecule compounds, and any small molecule compounds that may be used in the computer-assisted drug screening method provided by the present invention and may produce corresponding effects fall within the protection scope of the present invention.

[0049] In one embodiment, the modes of drug screening using computer-assisted drug screening technology include one or more of the following: protein-small molecule docking, protein-protein docking, and protein-nucleic acid docking.

[0050] In one embodiment, the protein-small molecule docking refers to a computational simulation process of docking the structures of proteins and small molecules (such as drug molecules) together through certain algorithms and programs. This process can be used to study the interaction between proteins and small molecules, as well as possible biological functions.

[0051] In protein-small molecule docking, software such as DOCK is usually used for computational simulation. DOCK is a highly automated drug design software that can achieve docking between small molecule ligands and biomacromolecule receptors. It uses a fragment-based scoring method to achieve fast and accurate docking. The basic algorithm of DOCK software includes two stages. The first stage is the low-precision stage, which mainly searches for a rough match between small molecule ligands and biomacromolecule receptors. The second stage is the high-precision stage, in which all side chain conformations are considered to calculate more accurate interaction energy. In the low-precision stage, DOCK software will randomly translate and rotate small molecule ligands, perform a certain number of rigid body moves, and then calculate the interaction energy. After outputting the lowest conformation, it enters the high-precision stage. In the high-precision stage, the program will perform more optimization and adjustments to achieve more accurate docking.

[0052] In one embodiment, the protein-protein docking refers to a computational simulation process of docking the structures of two proteins together through certain algorithms and programs. This process can be used to study the interaction between proteins and possible biological functions.

[0053] In protein-protein docking, RosettaDock is a commonly used docking software that uses a fragment-based scoring method to achieve fast and accurate protein docking. The software can achieve precise adjustment of side chain conformations during docking and consider a variety of complex interactions, such as hydrogen bonds, ionic bonds, hydrophobic interactions, etc. The basic algorithm of RosettaDock includes two stages. The first stage is the low-precision stage, which mainly searches for the degree of adaptation of the backbone shapes between the two proteins. The second stage is the high-precision stage, in which all side chain conformations are considered to calculate more accurate interaction energy. In the low-precision stage, the program randomly translates and rotates a component of a protein molecule, performs a certain number of rigid body moves, and then calculates the interaction energy. After outputting the lowest conformation, it enters the high-precision stage. In the high-precision stage, the program performs 50 MCMPCycles: rearranges the conformation and minimizes the interaction energy, which is used as the initial starting conformation.

[0054] In one embodiment, the protein-nucleic acid docking refers to a computational simulation process of docking the structures of proteins and nucleic acids (such as DNA or RNA) together through certain algorithms and programs. This process can be used to study the interactions between proteins and nucleic acids, as well as possible biological functions.

[0055] In protein-nucleic acid docking, software such as NAflex is usually used for computational simulation. NAflex is a software developed specifically for nucleic acid structure prediction and design, which can achieve accurate modeling and docking of DNA or RNA molecules. NAflex software uses a fragment-based scoring method to achieve fast and accurate docking. It takes into account a variety of complex interactions, such as hydrogen bonds, ionic bonds, hydrophobic interactions, etc., and can achieve precise adjustment of side chain conformations during docking. The basic algorithm of NAflex software includes two stages. The first stage is the low-precision stage, which mainly searches for rough matches between proteins and nucleic acids. The second stage is the high-precision stage, in which all side chain conformations are considered and more accurate interaction energies are calculated. In the low-precision stage, NAflex software randomly translates and rotates nucleic acid molecules, performs a certain number of rigid body moves, and then calculates the interaction energy. After outputting the lowest conformation, it enters the high-precision stage. In the high-precision stage, the program will perform more optimization and adjustments to achieve more accurate docking.

[0056] Figure 4 Schematic diagram of a computer-assisted drug screening system based on miR-223-3p and KIF4A provided by an embodiment of the present invention. Specifically, the system includes:

[0057] Data acquisition unit: obtain miR-223-3p and KIF4A data;

[0058] Site determination unit: selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug;

[0059] Drug screening unit: computer-assisted drug screening method is used to obtain candidate drugs targeting the binding site.

[0060] In one embodiment, the method for computer-assisted drug screening comprises:

[0061] Obtaining the binding site of miR-223-3p and KIF4A;

[0062] Protein analogs / nucleic acid analogs / antibodies / RNA drugs are screened through the binding site to obtain candidate drugs.

[0063] In one embodiment, the method for computer-assisted drug screening comprises:

[0064] Obtaining the binding site of miR-223-3p and KIF4A;

[0065] Based on the spatial structure of the binding site of miR-223-3p and KIF4A, screening small molecule compounds with similar structures in the molecular database;

[0066] The screened small molecule compounds are subjected to molecular docking with the KIF4A protein to calculate the affinity or binding energy of the small molecule compounds targeting the KIF4A protein to obtain the score of each small molecule compound, and the candidate drugs are obtained by ranking according to the score.

[0067] In one embodiment, the drugs screened by the computer-assisted drug screening system are used to treat breast cancer.

[0068] Figure 5 Schematic diagram of a computer-assisted drug screening device based on miR-223-3p and KIF4A provided by an embodiment of the present invention. Specifically, the device includes:

[0069] A memory and a processor, wherein the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, the computer-assisted drug screening method based on miR-223-3p and KIF4A as described above of the present invention is implemented.

[0070] An embodiment of the present invention further provides a computer-readable storage medium having a computer program stored thereon. When the computer program is executed by a processor, the computer-assisted drug screening method based on miR-223-3p and KIF4A as described above in the present invention is implemented.

[0071] Those skilled in the art can clearly understand that, for the convenience and brevity of description, the specific working processes of the systems, devices and units described above can refer to the corresponding processes in the aforementioned method embodiments and will not be repeated here.

[0072] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.

[0073] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0074] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.

[0075] A person of ordinary skill in the art can understand that all or part of the steps in the various methods of the above embodiments can be completed by instructing related hardware through a program, and the program can be stored in a computer-readable storage medium, and the storage medium may include: a read-only memory (ROM), a random access memory (RAM), a disk or an optical disk, etc.

[0076] A person skilled in the art can understand that all or part of the steps in the above-mentioned embodiment method can be completed by instructing related hardware through a program, and the program can be stored in a computer-readable storage medium. The above-mentioned storage medium can be a read-only memory, a disk or an optical disk, etc.

[0077] The above is a detailed introduction to a computer device provided by the present invention. For a person skilled in the art, according to the concept of the embodiments of the present invention, there may be changes in the specific implementation method and application scope. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A computer-assisted drug screening method based on miR-223-3p and KIF4A, characterized in that: The computer-assisted drug screening method based on miR-223-3p and KIF4A comprises: Obtain miR-223-3p and KIF4A gene data; Selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug; Using a computer-assisted drug screening method to obtain candidate drugs targeting the binding site; Optionally, the candidate drug is used to treat breast cancer.

2. The computer-assisted drug screening method based on miR-223-3p and KIF4A according to claim 1, characterized in that: The computer-assisted drug screening method comprises: The binding site of miR-223-3p and KIF4A was obtained.

3. Screen protein analogs / nucleic acid analogs / antibodies / RNA drugs through the binding sites to obtain candidate drugs. The computer-assisted drug screening method based on miR-223-3p and KIF4A according to claim 2, characterized in that The protein analogs / nucleic acid analogs / antibodies / RNA include siRNA, shRNA, dsRNA, microRNA, antisense nucleic acid, antibodies, polypeptides, protein analogs, and peptide analogs.

4. The computer-assisted drug screening method based on miR-223-3p and KIF4A according to claim 1, characterized in that: The computer-assisted drug screening method comprises: Obtaining the binding site of miR-223-3p and KIF4A; Based on the spatial structure of the binding site of miR-223-3p and KIF4A, screening small molecule compounds with similar structures in the molecular database; The screened small molecule compounds are subjected to molecular docking with the KIF4A protein to calculate the affinity or binding energy of the small molecule compounds targeting the KIF4A protein to obtain the score of each small molecule compound, and the candidate drugs are obtained by ranking according to the score.

5. A computer-assisted drug screening system based on miR-223-3p and KIF4A, characterized in that: The computer-aided drug screening system comprises: Data acquisition unit: obtain miR-223-3p and KIF4A data; Site determination unit: selecting the binding site of miR-223-3p and KIF4A as the binding site of the targeted drug; Drug screening unit: computer-assisted drug screening method is used to obtain candidate drugs targeting the binding site.

6. The computer-assisted drug screening system based on miR-223-3p and KIF4A according to claim 5, characterized in that: The computer-assisted drug screening method comprises: Obtaining the binding site of miR-223-3p and KIF4A; Protein analogs / nucleic acid analogs / antibodies / RNA drugs are screened through the binding site to obtain candidate drugs.

7. The computer-assisted drug screening system based on miR-223-3p and KIF4A according to claim 5, characterized in that: The computer-assisted drug screening method comprises: Obtaining the binding site of miR-223-3p and KIF4A; Based on the spatial structure of the binding site of miR-223-3p and KIF4A, screening small molecule compounds with similar structures in the molecular database; The screened small molecule compounds are subjected to molecular docking with the KIF4A protein to calculate the affinity or binding energy of the small molecule compounds targeting the KIF4A protein to obtain the score of each small molecule compound, and the candidate drugs are obtained by ranking according to the score.

8. A computer-assisted drug screening device based on miR-223-3p and KIF4A, characterized in that: The device comprises: A memory and a processor, wherein the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, the computer-assisted drug screening method based on miR-223-3p and KIF4A according to any one of claims 1 to 4 is implemented.

9. A computer-readable storage medium, characterized in that: The computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the computer-assisted drug screening method based on miR-223-3p and KIF4A according to any one of claims 1 to 4 is implemented.

10. Use of candidate drugs screened by the computer-assisted drug screening method based on miR-223-3p and KIF4A according to any one of claims 1 to 4 in the treatment of breast cancer.

Images